---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-003513"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2025-05-14T23:59:59+00:00"
generated_at: "2026-05-21T08:38:18.171883+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences Q1 2025: net loss $0.9M, revenue $0.6M (+16%), cash $5.2M

## Summary
- Net loss of ~$0.9M for Q1 2025; revenue increased 16.1% to ~$0.6M from $0.5M in Q1 2024.
- Total operating costs decreased 13.7% to ~$1.5M, primarily due to lower personnel costs after CEO/CSO departures in mid-2024.
- Cash position of $5.2M at quarter end; no guidance or dividend changes.
- Advancing DNase I platform; collaboration with PeriNess for exploratory studies in osteosarcoma, Ewing sarcoma, and pancreatic carcinoma.

## SEC filing metadata
- accession: 0001683168-25-003513
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2025-05-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316825003513/0001683168-25-003513-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316825003513/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-003513
- JSON: https://secwatch.observer/filing/0001683168-25-003513.json
- Plain text: https://secwatch.observer/filing/0001683168-25-003513.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.